Indian Pharma Stocks Slide Amid U.S. Tariff Announcement, Trade Tensions Escalate

Indian pharmaceutical companies saw share prices decline sharply following President Donald Trump's announcement of 100% tariffs on imported branded medications. SUN Pharmaceutical dropped 2.5%, while Divi’s Laboratories fell 3.5%, dragging the Nifty Pharma Index down over 2%.

Industry experts downplayed the operational impact, noting Indian firms primarily export generic drugs to the U.S. Sudarshan Jain of the Indian Pharmaceutical Alliance told CNBC the tariffs WOULD have limited effect, yet investor anxiety persists amid broader trade disputes.

Trade tensions between the U.S. and India continue to escalate. WHITE House trade advisor Peter Navarro linked recent tariff hikes to India’s Russian oil purchases, calling the Ukraine conflict "Modi’s war." Sectors like textiles, gems, and marine products have borne the brunt, though India’s domestic-driven economy cushions the overall blow.